Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)

• Status: Completed
• Trial end date: 2001-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to evaluate the treatment effect of montelukast 10 mg taken in the morning, versus placebo, in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active control.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Loratadine; Montelukast

Criteria

Inclusion Criteria:

• Patient has a history of seasonal allergic rhinitis that worsens during the study season

• Patient is a nonsmoker

• Patient is in good health physical and mental health

Exclusion Criteria:

• Patient is hospitalized

• Patient is a woman who is < 8 weeks postpartum or is breastfeeding

• Patient plans to move or vacation away during the study

• Patient has had any major surgery with in past 4 weeks

• Patient is a current or past abuser of alcohol or illicit drugs